| For: | Papadopoulou A, Papadopoulos KI. Successful lifestyle modifications may underlie umbilical cord-mesenchymal stromal cell effects in type 2 diabetes mellitus. World J Diabetes 2023; 14(3): 347-351 [PMID: 37035224 DOI: 10.4239/wjd.v14.i3.347] |
|---|---|
| URL: | https://www.wjgnet.com/1948-0210/full/v14/i3/347.htm |
| Number | Citing Articles |
| 1 |
Li Jia, Na Li, Vincent van Unen, Jaap-Jan Zwaginga, Jerry Braun, Pieter Hiemstra, Frits Koning, P. Khedoe, Jan Stolk. Pulmonary and Systemic Immune Profiles Following Lung Volume Reduction Surgery and Allogeneic Mesenchymal Stromal Cell Treatment in Emphysema. Cells 2024; 13(19) doi: 10.3390/cells13191636
|
| 2 |
Miao Zhu, Ruifang Guan, Guo Ma. Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1282584
|
| 3 |
Gumpeny R Sridhar, Suresh Anne, Lakshmi Gumpeny, Sanjana S N Narasimhadevara. Umbilical cord mesenchymal stem cells in diabetes mellitus. World Journal of Clinical Cases 2026; 14(23): 121196 doi: 10.12998/wjcc.121196
|
| 4 |
Xue Yu, Xilin Liu, Hong Li. Nutrient metabolism and complications of type 2 diabetes mellitus: implications for rehabilitation and precision care. Frontiers in Nutrition 2025; 12 doi: 10.3389/fnut.2025.1699259
|
| 5 |
Priyamvada Amol Arte, Kanchanlata Tungare, Mustansir Bhori, Renitta Jobby, Jyotirmoi Aich. Treatment of type 2 diabetes mellitus with stem cells and antidiabetic drugs: a dualistic and future-focused approach. Human Cell 2023; 37(1) doi: 10.1007/s13577-023-01007-0
|